OBIO vs. DCTH, TMCI, OM, NPCE, CLPT, NNOX, SKIN, ZIMV, BSGM, and SNWV
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Delcath Systems (DCTH), Treace Medical Concepts (TMCI), Outset Medical (OM), NeuroPace (NPCE), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), Beauty Health (SKIN), ZimVie (ZIMV), Biosig Technologies (BSGM), and Sanuwave Health (SNWV). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs. Its Competitors
Delcath Systems (NASDAQ:DCTH) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.
Delcath Systems has a net margin of -26.38% compared to Orchestra BioMed's net margin of -2,297.85%. Delcath Systems' return on equity of -29.44% beat Orchestra BioMed's return on equity.
Delcath Systems has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.
Delcath Systems presently has a consensus price target of $24.00, suggesting a potential upside of 111.64%. Orchestra BioMed has a consensus price target of $14.20, suggesting a potential upside of 386.30%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Delcath Systems.
In the previous week, Orchestra BioMed had 2 more articles in the media than Delcath Systems. MarketBeat recorded 3 mentions for Orchestra BioMed and 1 mentions for Delcath Systems. Orchestra BioMed's average media sentiment score of 1.13 beat Delcath Systems' score of 0.65 indicating that Orchestra BioMed is being referred to more favorably in the news media.
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 53.6% of Orchestra BioMed shares are held by institutional investors. 17.4% of Delcath Systems shares are held by insiders. Comparatively, 8.1% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Delcath Systems has higher revenue and earnings than Orchestra BioMed. Delcath Systems is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Summary
Delcath Systems beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 7/13/2025 by MarketBeat.com Staff
Free OBIO Stock Alerts